String Bio, the Indian biotech firm, has achieved self-determined Generally Recognized as Safe (GRAS) status for its microbial protein, PRO-DG to be used in crustacean feed in the U.S. It is confirmed by an independent panel of experts who thoroughly evaluated the published safety data supporting the microbial protein intended use.
Governed by the U.S. Food and Drug Administration (FDA), GRAS status signifies a high standard for ingredient approval in both feed and food. According to the media statement, the microbial protein contains approximately 70% protein derived from methanotrophic bacteria and is produced using String Bio’s patented String Integrated Methane Platform.
The GRAS status sets String Bio apart in the alternative protein industry. The achievement, which involved over two years of detailed scientific documentation and safety studies, underscores the company’s dedication to science-based innovation.
Ezhil Subbian, CEO of String Bio, noted that the GRAS status will facilitate the commercialization of PRO-DG in the U.S., creating new market opportunities and supporting growth. Many countries consider GRAS status a strong indicator of thorough testing and high standards, making this milestone a major enhancement for String Bio’s presence in the feed sector.
Source: The Business line
